Source URL: https://www.theregister.com/2025/01/08/dna_sequencer_vulnerabilities/
Source: The Register
Title: DNA sequencers found running ancient BIOS, posing risk to clinical research
Feedly Summary: Devices on six-year-old firmware vulnerable to takeover and destruction
Argentine cybersecurity shop Eclypsium claims security issues affecting leading DNA sequencing devices could lead to disruptions in crucial clinical research.…
AI Summary and Description: Yes
Summary: The text highlights significant security vulnerabilities in the iSeq 100 DNA sequencing device, revealing the potential for malware and ransomware attacks due to an insecure BIOS implementation. The insights are crucial for cybersecurity professionals, particularly in the healthcare and biotechnology sectors, underscoring the growing threat of firmware-targeted attacks.
Detailed Description:
The report discusses the findings of Eclypsium researchers regarding the iSeq 100 DNA sequencing device by Illumina, which is used in critical clinical research. The experts detailed how the device’s BIOS was outdated and insecure, exposing it to various cybersecurity threats. Key points include:
– **Vulnerability in BIOS**: The iSeq 100 is operating on a 2018 BIOS version with known vulnerabilities, which could open opportunities for malware and ransomware attacks.
– **Compatibility Support Mode**: The device was found to be incorrectly configured to allow older BIOS firmware to be booted, worsening its security stance.
– **Lack of Protections**: Essential security features like Secure Boot were disabled, and there were no mechanisms to protect firmware read/write permissions, allowing attackers undisputed access to modify firmware.
– **Growing Threat Landscape**: The researchers indicated that attacks targeting firmware have sharply increased, particularly as state-based actors and ransomware groups shift focus to exploit BIOS/UEFI vulnerabilities.
– **Real-World Risks**: The possibility of a firmware attack could disrupt critical research in genetics, oncology, and vaccine development, posing significant implications for public health.
– **Historical Context**: The text references known attacks on firmware, including exploits by Hacking Team and the implications of the 2023 FDA Class II recall related to similar vulnerabilities in the iSeq 100.
– **Broad Implications**: Given that devices made by various manufacturers may share similar vulnerabilities, the problem could extend beyond Illumina’s sequencers, affecting a wide array of medical devices, and should prompt urgent action from stakeholders.
– **Industry Response**: Illumina has been made aware of the vulnerabilities and has communicated fixes to its customers, indicating an effort to mitigate the security risks identified by Eclypsium.
Overall, this analysis serves as a critical reminder for security and compliance professionals in medical technology and research fields to prioritize firmware security and adopt proactive measures to defend against evolving threats.